LCC is an international, chemistry-based CRO on a mission to accelerate your discovery. Its technologies unlock thousands of functionalised (chiral) building blocks that cover some of the gaps in existing 3D chemical space through a combination of novel scaffolds and novel variants of privileged scaffolds.
LCC’s products are categorised to serve specific hit-identification screening technologies, including:
(a) monomers and scaffolds for DEL synthesis,
(b) collections of fragments for FBLD (including covalent, fluoro derivatives and enantioprobes),
(c) semi-flexible linkers for PROTACs,
(d) chiral API and intermediates for 'Me-Too' drug discovery.
With a variety of core technologies and strengths, and facilities that allow production from mg to multi-kg scale, LCC's product pipeline is continuously evolving. Through an ethos of purposeful curiosity, LCC’s goal is to help the development of high-quality drugs, in order to bring new drugs to market faster, better and easier.
Wednesday, 18th November, 2020
10:00am GMT (UTC+0)
hosted by Lilly Xu, Ph.D. Senior Vice President, DMPK & Exploratory Toxicology Dept, ChemPartner